Egyptian International Pharmaceutical Industries Company (EGX:PHAR)
Egypt · Delayed Price · Currency is EGP 78.50
-0.98 (-1.23%)
At close: Feb 2, 2026
EGX:PHAR Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 9,296 | 7,591 | 5,232 | 3,955 | 3,409 | 2,886 | |
Revenue Growth (YoY) | 32.76% | 45.09% | 32.27% | 16.03% | 18.13% | -15.40% |
Cost of Revenue | 5,268 | 4,244 | 2,983 | 2,397 | 1,957 | 1,675 |
Gross Profit | 4,028 | 3,346 | 2,248 | 1,558 | 1,452 | 1,211 |
Selling, General & Admin | 1,175 | 1,065 | 788.09 | 683.2 | 566.08 | 547.58 |
Research & Development | 75.68 | 70.45 | 43.23 | 43.68 | 34.96 | 20.87 |
Other Operating Expenses | 181.7 | 378.57 | 167.2 | 134.35 | 60.79 | 55.35 |
Operating Expenses | 1,763 | 1,844 | 1,038 | 896.23 | 674.83 | 623.8 |
Operating Income | 2,266 | 1,503 | 1,211 | 662 | 776.85 | 587.32 |
Interest Expense | -1,267 | -928.54 | -388.52 | -195.42 | -136.25 | -83.16 |
Interest & Investment Income | 386.39 | 72.05 | 26.24 | 57.77 | 32.11 | 40.57 |
Earnings From Equity Investments | 151.58 | 151.58 | 74.51 | - | - | 37.18 |
Currency Exchange Gain (Loss) | 118.64 | 699.88 | 139.63 | 286.4 | -6.25 | -11.55 |
Other Non Operating Income (Expenses) | 70.38 | 11.04 | 1.51 | -20.62 | -24.04 | 13.37 |
EBT Excluding Unusual Items | 1,726 | 1,509 | 1,064 | 790.13 | 642.41 | 583.74 |
Gain (Loss) on Sale of Assets | 1.54 | 0.22 | 4.69 | 3.7 | 2.78 | 3.8 |
Pretax Income | 1,728 | 1,509 | 1,069 | 793.83 | 645.19 | 587.55 |
Income Tax Expense | 459.55 | 411.83 | 245.62 | 150.07 | 156.9 | 100.15 |
Earnings From Continuing Operations | 1,268 | 1,097 | 823.31 | 643.76 | 488.29 | 487.4 |
Minority Interest in Earnings | -11.01 | -1.21 | -0.99 | -0.78 | -0.53 | -0.89 |
Net Income | 1,257 | 1,096 | 822.32 | 642.98 | 487.75 | 486.51 |
Net Income to Common | 1,257 | 1,096 | 822.32 | 642.98 | 487.75 | 486.51 |
Net Income Growth | 8.11% | 33.25% | 27.89% | 31.83% | 0.25% | -27.45% |
Shares Outstanding (Basic) | 169 | 149 | 149 | 99 | 99 | 98 |
Shares Outstanding (Diluted) | 169 | 149 | 149 | 99 | 99 | 98 |
Shares Change (YoY) | 13.44% | - | 50.00% | - | 1.64% | -1.61% |
EPS (Basic) | 7.45 | 7.37 | 5.53 | 6.48 | 4.92 | 4.99 |
EPS (Diluted) | 7.45 | 7.37 | 5.53 | 6.48 | 4.92 | 4.99 |
EPS Growth | -4.71% | 33.25% | -14.74% | 31.83% | -1.36% | -26.26% |
Free Cash Flow | -1,458 | -4,121 | -2,198 | -859.77 | -53.27 | -38.7 |
Free Cash Flow Per Share | -8.64 | -27.70 | -14.77 | -8.67 | -0.54 | -0.40 |
Dividend Per Share | 1.500 | 1.500 | 1.000 | 1.000 | 1.500 | - |
Dividend Growth | 50.00% | 50.00% | - | -33.33% | - | - |
Gross Margin | 43.33% | 44.09% | 42.98% | 39.40% | 42.59% | 41.97% |
Operating Margin | 24.37% | 19.79% | 23.14% | 16.74% | 22.79% | 20.35% |
Profit Margin | 13.52% | 14.44% | 15.72% | 16.26% | 14.31% | 16.86% |
Free Cash Flow Margin | -15.68% | -54.29% | -42.01% | -21.74% | -1.56% | -1.34% |
EBITDA | 2,370 | 1,599 | 1,314 | 759.39 | 867.73 | 726.89 |
EBITDA Margin | 25.50% | 21.07% | 25.12% | 19.20% | 25.46% | 25.19% |
D&A For EBITDA | 104.31 | 96.53 | 103.17 | 97.39 | 90.88 | 139.57 |
EBIT | 2,266 | 1,503 | 1,211 | 662 | 776.85 | 587.32 |
EBIT Margin | 24.37% | 19.79% | 23.14% | 16.74% | 22.79% | 20.35% |
Effective Tax Rate | 26.60% | 27.30% | 22.98% | 18.90% | 24.32% | 17.04% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.